Navigation Links
Medac Pharma, Inc. Announces Multiple Poster Presentations During the 2013 ACR/ARHP Annual Meeting
Date:10/21/2013

CHICAGO, Oct. 21, 2013 /PRNewswire/ -- Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced today that data from two recently completed clinical trials for its lead product will be presented during the 2013 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting to be held October 25 – 30, in San Diego, CA at the San Diego Convention Center.

"We're encouraged by the data each of these studies have generated as it provides additional validation for our unique approach to delivering a broad dosing range of methotrexate to patients with rheumatoid arthritis," remarked Terri Shoemaker, President and CEO of Medac Pharma, Inc.  "Our primary goal is to provide this extremely underserved patient population with a more personalized delivery technique to managing their disease, and we believe we're on track for accomplishing that through our unique approach."

The posters will highlight Medac Pharma Inc.'s rationale for the development of its lead product by presenting data on relative bioavailability and ease of self-administration.

Monday, October 28, 2013:Title:Successful Self-Administration of Methotrexate In Rheumatoid Arthritis Patients Using a Prefilled Autoinjector PenTime:Available: 9:00 a.m. PT – 11:00 a.m. PTPoster:Abstract #1354Location:Exhibit Hall B2-C-D (8:30 a.m. PT – 4:00 p.m. PT)Title:Subcutaneous Administration Of Methotrexate With a Prefilled Autoinjector Pen Results In a Higher Relative Bioavailability Compared To Oral Administration Of MethotrexateTime:Available: 9:00 a.m. PT – 11:00 a.m. PTPoster:Abstract # 1355Location:Exhibit Hall B2-C-D (8:30 a.m. PT – 4:00 p.m. PT)About Medac Pharma, Inc.Medac Pharma, Inc. is the wholly owned subsidiary of medac GmbH, a well known and respected global pharmaceutical company that has been making scientific and therapeutic discoveries for more than 40 years.

Medac Pharma Inc. is focused on developing therapies with the potential to make meaningful differences in patients' lives.  The company's approach is to improve existing agents by enhancing the mode of delivery, addressing safety profiles and inventing ways to maximize efficacy.

For more information, please visit www.medacpharma.com.

For Media:
Tiberend Strategic Advisors, Inc.
Andrew Mielach
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Medac Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pre-Market Analysis: MannKind, Galena Biopharma, Ariad Pharma, and Novavax
2. Todays Research: Delcath Systems, Astex Pharma, BioMarin Pharma, and Akorn
3. Stipulation Of Dismissal Of Claims By Plaintiff Cornerstone Biopharma, Inc.
4. Todays Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
5. NovoBioPharma, Partnership of Top Life Science Experts, Launches
6. Zosano Pharma, Inc. Appoints Nandan Oza as Chief Operations Officer
7. Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.
8. Zosano Pharma, Inc. Announces Key Strategic Hire
9. DFH Pharma, USA Partners with Hetero Group, INDIA to Develop 2nd Generation HIV Maturation Inhibitor Drugs
10. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
11. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... addition of the "Structural Electronics 2015-2025: Applications, ... In-Mold Electronics, Smart ... Integrated Photovoltaics Structural electronics involves ... as load-bearing, protective structures, replacing dumb structures such ...
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
Breaking Medicine News(10 mins):